Latest Data & Signals Issued

Signal Type Signal Value Data
Score 5.994 7 days ( -26.54 % )
Last Price $9.37 7.95 %
High/ Low $8.77 - $10.55 43.44%
Chg 7 Days 38.20 % $6.78 $9.37
Chg 30 Days 1,991.52 % $0.448 $9.37
Chg 12 mos 837.00 % $1.00 $9.37
Trend - 3 mos 178.58 % Width: 616.48 %
Trend - 12 mos 17.31 % Width: 468.02 %
Pred. range - 3 mos $3.64 - $26.10 -61.12 % - 178.58 %
Pred. range - 12 mos $0.443 - $2.52 -95.27 % - -73.15 %
Short MA avg 3 mos Buy 2024-03-13 - 11 days
Long MA avg 3 mos Buy 2024-03-13 - 11 days
Short/Long MA avg 3 mos Buy 2024-03-13 - 11 days
Short MA avg 12 mos Buy 2024-03-13 - 11 days
Long MA avg 12 mos Buy 2024-03-13 - 11 days
Short/Long MA avg 12 mos Buy 2024-03-13 - 11 days
Pivot Short Buy 2024-03-13 - 11 days
Bollinger Buy 2023-12-13 - 72 days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Outlook Therapeutics Inc.

Outlook Therapeutics. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice... OTLK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT